局部晚期非小细胞肺癌纵隔肿瘤负荷与淋巴播散的影响:多中心随机PET-Plan试验的二次分析
该研究为前瞻性随机2期PET-Plan试验(ARO-2009-09;NCT00697333)的二次分析,纳入按方案治疗的172例局部晚期非小细胞肺癌(NSCLC)患者,评估纵隔肿瘤负荷与淋巴播散对预后的影响。中位随访41.1个月(95%CI 33.8-50.4),PET阳性淋巴结站数多者总生存(HR=1.09;95%CI 0.99-1.18;p=0.05)和无进展生存(HR=1.12;95%CI 1.04-1.20;p=0.003)更差;B组中淋巴结站处方剂量与无局部进展生存显著相关(HR=0.45;95%CI 0.24-0.85;p=0.01)。
要点
- PET阳性淋巴结站数多者总生存(HR=1.09;95%CI 0.99-1.18;p=0.05)和无进展生存(HR=1.12;95%CI 1.04-1.20;p=0.003)更差。
- 累及第3梯队淋巴结站者无进展生存更差(HR=2.22;95%CI 1.16-4.28;p=0.02)。
- B组中淋巴结站处方剂量与无局部进展生存显著相关(HR=0.45;95%CI 0.24-0.85;p=0.01)。
核心结论
- 纵隔肿瘤负荷和淋巴受累模式影响接受根治性放化疗的局部晚期NSCLC患者的结局。
- 提高淋巴结剂量未改善总生存,但在接受基于PET的剂量递增放疗的患者中改善了无局部进展生存。
研究设计与样本
- 研究为前瞻性随机2期PET-Plan试验(ARO-2009-09;NCT00697333)的二次分析。
- 纳入按方案治疗的172例局部晚期NSCLC患者。
- 患者接受等毒剂量递增放化疗,总剂量60-74 Gy,分30-37次,在正常组织约束下尽可能提高剂量。
- 放疗计划基于18F-FDG PET/CT:A组靶向所有CT阳性淋巴结(短轴直径>10 mm)所在淋巴结站,即使PET阴性;B组仅靶向PET阳性淋巴结所在淋巴结站。
- 淋巴结站分为梯队1(同侧肺门)、2(同侧4站和7站)、3(其余纵隔、对侧肺门)。
主要发现
- 中位随访时间(95%CI)为41.1(33.8-50.4)个月。
- PET阳性淋巴结站绝对数多的患者总生存更差(HR=1.09;95%CI 0.99-1.18;p=0.05),无进展生存更差(HR=1.12;95%CI 1.04-1.20;p=0.003),与治疗分组无关。
- 在所有患者中,淋巴结处方放疗剂量与任何终点均不相关。
- 在B组(基于PET的选择性淋巴结照射)中,每个淋巴结站的处方放疗剂量与无局部进展生存显著相关(HR=0.45;95%CI 0.24-0.85;p=0.01)。
- 累及第3梯队淋巴结站的患者无进展生存更差(HR=2.22;95%CI 1.16-4.28;p=0.02),同样与分组无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this secondary analysis of the prospective randomized phase 2 PET-Plan trial (ARO-2009-09; NCT00697333) was to evaluate the impact of mediastinal tumor burden and lymphatic spread in patients with locally advanced non-small-cell lung cancer (NSCLC). METHODS: All patients treated per protocol (n = 172) were included. Patients received isotoxically dose-escalated chemoradiotherapy up to a total dose of 60-74 Gy in 30-37 fractions, aiming as high as possible while adhering to normal tissue constraints. Radiation treatment (RT) planning was based on an 18F-FDG PET/CT targeting all lymph node (LN) stations containing CT positive LNs (i.e. short axis diameter > 10 mm), even if PET-negative (arm A) or targeting only LN stations containing PET-positive nodes (arm B). LN stations were classified into echelon 1 (ipsilateral hilum), 2 (ipsilateral station 4 and 7), and 3 (rest of the mediastinum, contralateral hilum). The endpoints were overall survival (OS), progression-free survival (PFS), and freedom from local progression (FFLP). RESULTS: The median follow-up time (95 % confidence interval [CI]) was 41.1 (33.8 - 50.4) months. Patients with a high absolute number of PET-positive LN stations had worse OS (hazard ratio [HR] = 1.09; 95 % CI 0.99 - 1.18; p = 0.05) and PFS (HR = 1.12; 95 % CI 1.04 - 1.20; p = 0.003), irrespective of treatment arm allocation. The prescribed RT dose to the LNs did not correlate with any of the endpoints when considering all patients. However, in patients in arm B (i.e., PET-based selective nodal irradiation), prescribed RT dose to each LN station correlated significantly with FFLP (HR=0.45; 95 % CI 0.24-0.85; p = 0.01). Furthermore, patients with involvement of echelon 3 LN stations had worse PFS (HR = 2.22; 95 % CI 1.16-4.28; p = 0.02), also irrespective of allocation. CONCLUSION: Mediastinal tumor burden and lymphatic involvement patterns influence outcome in patients treated with definitive chemoradiotherapy for locally advanced NSCLC. Higher dose to LNs did not improve OS, but did improve FFLP in patients treated with PET-based dose-escalated RT.
引用
- Gkika E, Dejonckheere CS, Sahlmann J, et al. Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial. Radiother Oncol. 2024. PMID: 39236984. doi:10.1016/j.radonc.2024.110521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。